- Previous Close
2.7600 - Open
2.7200 - Bid 1.9500 x 200
- Ask 3.5000 x 200
- Day's Range
2.7000 - 2.7200 - 52 Week Range
2.4700 - 20.2750 - Volume
2,598 - Avg. Volume
92,020 - Market Cap (intraday)
3.525M - Beta (5Y Monthly) 3.83
- PE Ratio (TTM)
-- - EPS (TTM)
-302.6300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
www.redhillbio.com53
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: RDHL
View More
Performance Overview: RDHL
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RDHL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RDHL
View MoreValuation Measures
Market Cap
3.62M
Enterprise Value
-3.10M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.96
Price/Book (mrq)
59.40
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-44.88%
Return on Equity (ttm)
-1,708.61%
Revenue (ttm)
3.71M
Net Income Avi to Common (ttm)
-30.17M
Diluted EPS (ttm)
-302.6300
Balance Sheet and Cash Flow
Total Cash (mrq)
7.28M
Total Debt/Equity (mrq)
914.75%
Levered Free Cash Flow (ttm)
-5.39M